The minimally invasive spine device maker aims to use funds from the sale to advance its platform for spinal stenosis treatments, according to the release. The scale and scope of the deal are not disclosed, and will include cash and contingent payments as well as a long-term licensing agreement.
VertiFlex is currently conducting an investigational device exemption trial for its Superion Interspinous Spacer system.
More Articles on Devices:
41 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in February
Dr. Stephen Cook Named to Precision Spine Board of Directors
Nexxt Spine Consolidates, Relocates Headquarters
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.